Sanofi promises it's committed to Afrezza; Merck puts Gerberding in public health comms post; GSK files for new Volibris use;

> Sanofi ($SNY) Chairman Serge Weinberg assured Goldman Sachs analysts that the French drugmaker remains committed to launching and marketing MannKind's ($MNKD) new inhaled insulin product Afrezza. Report

> Merck ($MRK) tapped former CDC chief Julie Gerberding as its EVP for strategic communications, global public policy and population health, a new position; previously she headed up the company's vaccines unit. Report

> GlaxoSmithKline ($GSK) asked European regulators to expand use of its hypertension drug Volibris for use in combination therapy for pulmonary arterial hypertension patients. Report

> ViiV Healthcare asked Japanese regulators to approve its single pill HIV regimen Triumeq, comprising dolutegravir, abacavir and lamivudine; it won FDA approval in September. Report

> Lundbeck said the FDA is reviewing its request to allow its long-acting antipsychotic Abilify Maintena to be injected into the deltoid muscle. Report

And Finally... Merck KGaA's drug unit rolled out an iPhone app to allow patients to scan meds to make sure they're not counterfeit. Report

Suggested Articles

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.